FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of ...

The integration of genomic testing into cancer screening enables diagnostics to break away from conventional, one-size-fits-all protocols.

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

Global Urology Imaging Systems Market OverviewThe global urology imaging systems market is expected to register steady growth ...

The Radioligand Therapy Market is projected to reach US$13 billion by 2030, growing at an estimated rate of 5%. Key drivers of this growth include the rising incidence of cancers such as prostate ...

Cost: New longevity portfolio includes core MRI for $999, $899 intro offer (about 30 minutes); core MRI plus head and neck ...